study group:Study Vaccine Administration

3 trials

Sponsors

The First People's Hospital of Anning (The Fourth People's Hospital of Kunming), Yunnan Provincial Center for Disease Control and Prevention

Conditions

Novel Coronavirus Pneumonia (COVID-19)Pertussis, diphtheria, tetanus, Haemophilus influenzae type b disease

Phase 1

Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Adsorbed Acellular DPT/Haemophilus influenzae type b Combination Vaccine

RecruitingChiCTR2300078982

Yunnan Provincial Center for Disease Control and PreventionPertussis, diphtheria, tetanus, Haemophilus influenzae type b disease

Start: 2023-12-15Updated: 2024-01-08

Phase 3

A Phase III Clinical Trial to Evaluate the Protection Efficacy, Safety and Immunogenicity of One Dose of RQ3013 in Population Aged 18-59 Years and above Who Have Received 3 Doses of COVID-19 Inactivated Vaccine

Active, not recruitingChiCTR2200067184

The First People's Hospital of Anning (The Fourth People's Hospital of Kunming)Novel Coronavirus Pneumonia (COVID-19)

Start: 2022-12-28Updated: 2023-05-15

A Immunobridging Clinical Trial of a booster dose of SARS-CoV-2 variants mRNA vaccine (Omicron XBB.1.5) in Population Aged 18 Years and Above

RecruitingChiCTR2300077397

Yunnan Provincial Center for Disease Control and PreventionNovel Coronavirus Pneumonia (COVID-19)

Start: 2023-11-09Updated: 2023-11-13

Related Papers

Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial.

2023-09-218 citations